The Clinical Curative Effect Study Of Shengui Capsule In The Treatment Of Patients With Coronary Heart Disease And Chronic Heart Failure With Yang Deficiency And Blood Stasis Syndrome

Background:Chronic Heart Failure(CHF)is the end stage of cardiovascular disease,and it hasrecei ved more and more attention because of its high morbidity and mortality.Coronary ath erosclerotic heart disease is one of the leading causes of chronic heart failure.With th e continuous research on the pathogenesis of chronic heart failure,its therapeutic goals have gradually shifted to protect cardiomyocytes and inhibit ventricular remodeling.D ue to the side effects of the treatment of heart failure drugs and individualized differe nces in patients,the long-term benefits of patients with heart failure have not impro ved significantly.Traditional Chinese medicine has unique advantages in the treatment of chronic heart failure,and it has a definite effect in improving patients’ clinical sy mptoms and improving patients’ quality of life.Objective:1.To verify the efficacy of Shengui Capsule in the treatment of patients with coronary heart disease and chronic heart failure with yang deficiency and blood stasis syndrom e.2.To explore the mechanism of Shengui Capsule in the treatment of chronic heart fail ure in patients with coronary heart disease.Methods:This study was conducted in Dongzhimen Hospital from September 2016 to February 2019 and diagnosed as a patient with heart failure due to coronary heart disease with yang deficiency and blood stasis syndrome.Randomized and controlled clinical research methods were used to include 57 patients with coronary heart disease and heart failur e according to the diagnostic criteria,including 30 in the treatment group and27 in th e control group.Both groups were treated with standardized western medicine treatment.On the basis of standardized western medicine treatment in the treatment group,Shen gui Capsule(main components:red ginseng,Chuanxiong,Guizhi)was given for8weeks.Th e Lee’s score,heart failure symptom score,other symptom scores,N-terminalB-brain n atriuretic peptide(NT-proBNP),cardiac ultrasound index(E/A value,LVSV,LVIDs)an d myocardial energy were observed before and after treatment.Consumptionvalue(ME E)change.Results:1.TCM syndrome scores:The TCM syndrome scores of the treatment group and the co ntrol group(Lee’s score,heart failure symptom score,other symptom scores)were sig nificantly lower than before treatment(P<0.001);Lee’s score,heart failure symptom sc ore and other treatment groups after treatment The score of symptom score wasbetter than that of the control group(P<0.05).The score of Lee score in the treatmen group was better than that of the control group(P<0.05).The scores of shortness ofbreath,f atigue and cold and coldness of the treatment group and the control group were signi ficantly lower than those before treatment(P<0.001).The improvement of shortness of breath and chills after treatment was better than that of the control group(P<0.05).2.Cardiac function:The cardiac function(NYHA classification)of the treatment group and the control group were lower than before,and the treatment group was better tha n the control group(P<0.05).The EF value of the treatment group was better than th at before treatment(P<0.001).The improvement before treatment(P<0.05),the treatme nt group was better than the control group(P<0.05);the treatment group NT-proBNP level was lower than before treatment(P<0.05).3.Echocardiographic index:The E/A value of the treatment group was lower than that before treatment(P<0.001),and the decrease was better than that of the control group(P<0.05).The stroke volume(LVSV)of the treatment group was better than that befo re treatment(P<0.001).The LVSV value was not improved(P>0.05).The left ventric ular end-systolic diameter(LVIDs)in the treatment group was better than that beforetr eatment(P<0.001).The LVIDs in the control group were better than those before trea tment(P<0.05).In the control group(P<0.05).4.Energy expenditure(MEE):The MEE of the treatment group was lower than that bef ore treatment(P<0.001),and the degree of reduction was better than that of the contr of group(P<0.01).Conclusion:1.Shengui Capsule can alleviate the patient’s clinical symptoms(Lee’s score,heart fail ure symptom score and other symptom scores)and improve heart function(NYHA clas sification);2.Shengui Capsule can improve the patient’s cardiac ultrasound index(EF,E/A and L VIDs)and reduce the value of NT-proBNP;3.Shengui Capsule can reduce the MEE value of patients.It is speculated that themech anism of action is to improve the cardiac function of patients by improving theenergy metabolism of cardiomyocytes.